Should GlaxoSmithKline Have Accepted Unilever's $68 Billion Consumer Health Offer?

Thanks, but no thanks. That was basically the response from GlaxoSmithKline (NYSE: GSK) to Unilever's (NYSE: UL) recent offer to buy its joint venture consumer health unit for $68 billion. In this Motley Fool Live video recorded on Jan. 19, Motley Fool contributors Keith Speights and Brian Orelli discuss whether they think GlaxoSmithKline should have accepted Unilever's offer.

Continue reading

Source Fool.com